Up to 80% of bleeds occur in the joints.1 Good thing ELOCTATE knows a thing or two.
1.6 median overall bleeds per year†
0 median joint bleeds per year†
~100% of target joints resolved in adults and adolescents treating with ELOCTATE prophylaxis‡
#1 prescribed extended half-life Factor VIII in the US 2
Talk to your doctor to see if ELOCTATE is right for you.
*ELOCTATE has been proven to help patients prevent bleeding episodes using a prophylaxis regimen.
†In the A-LONG study, 164 adults and adolescents ages 12-65 received ELOCTATE either every 3 to 5 days, once weekly, or on demand. The ASPIRE extension study included 150 people who completed A-LONG.
‡Data from patients treating prophylactically with ELOCTATE for at least 12 months, who had target joints at enrollment in ASPIRE. 234 out of 235 target joints were resolved. A target joint is defined as a major joint with 3 or more bleeding episodes in a consecutive 6-month period. Target joint resolution is defined as 2 or fewer spontaneous bleeds in a 12-month period.
1Srivastava A, Brewer AK, Mauser- Bunschoten EP, et al. Guidelines for the management of hemophilia. Haemophilia. 013;19:e1-47.
2#1 prescribed based on HTC reported data as of June 2020.
Community Relations and Education Managers (or CoRe, for short) live and work all across the United States. CoRe team members are parents, social workers or people with hemophilia. They're available to answer your questions, educate, or just to talk. Use our handy CoRe Locator to find the CoRe team member nearest you.
Let's stay in touch. We’ll occasionally send you important information on Hemophilia A and ELOCTATE. If you're new to ELOCTATE, we’ll send you a Bluetooth® speaker so you can listen to patient stories, or if you're already on ELOCTATE, we’ll send you this stylish cooler bag.
Whether you’re a total newbie or a total pro, there’s something to learn about ELOCTATE.
Pick your path below, then select the links to get going.
You know you're leaving the ELOCTATE website?
If you're okay with that, we're okay with that.
Come back soon!
You’re being directed to the ELOCTATE Healthcare Professional website. If you’re okay with that, we’re okay with that.
Come back soon!
INDICATION ELOCTATE® [Antihemophilic Factor (Recombinant), Fc Fusion Protein] is an injectable medicine that is used to help control and prevent bleeding in people with Hemophilia A (congenital Factor VIII deficiency). Your healthcare provider may give you ELOCTATE when you have surgery.
Important Safety Information and Indication
IMPORTANT SAFETY INFORMATION
Do not use ELOCTATE if you have had an allergic reaction to it in the past.
Tell your healthcare provider if you have or have had any medical problems, take any medicines, including prescription and non-prescription medicines, supplements, or herbal medicines, have any allergies, are breastfeeding, are pregnant or planning to become pregnant, or have been told you have inhibitors (antibodies) to Factor VIII.
Allergic reactions may occur with ELOCTATE. Call your healthcare provider or get emergency treatment right away if you have any of the following symptoms: difficulty breathing, chest tightness, swelling of the face, rash, or hives.
Your body can also make antibodies called "inhibitors" against ELOCTATE, which may stop ELOCTATE from working properly.
Additional common side effects of ELOCTATE are headache, rash, joint pain, muscle pain and general discomfort.
If you have risk factors for developing abnormal blood clots in your body, such as an indwelling venous catheter, treatment with Factor VIII may increase this risk.
These are not all the possible side effects of ELOCTATE. Talk to your healthcare provider right away about any side effect that bothers you or that does not go away, or if bleeding is not controlled after using ELOCTATE.
ELOCTATE® [Antihemophilic Factor (Recombinant), Fc Fusion Protein] is an injectable medicine that is used to help control and prevent bleeding in people with Hemophilia A (congenital Factor VIII deficiency). Your healthcare provider may give you ELOCTATE when you have surgery.